Valuation : LB Pharmaceuticals Inc

Market Cap 1.59B 1.37B 1.29B 1.18B 2.2B 151B 2.21B 15.26B 5.9B 77.09B 5.98B 5.85B 246B P/E 2026 *
-8.65x
P/E 2027 * -9.99x
Enterprise Value 1.24B 1.06B 1B 913M 1.71B 117B 1.71B 11.86B 4.58B 59.89B 4.64B 4.54B 191B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.76%
Yield 2026 *
-
Yield 2027 * -
1 day+3.83%
1 week+4.40%
Current month+4.40%
1 month+2.79%
3 months+72.94%
6 months+107.49%
Current year+121.65%
1 week 46.44
Extreme 46.44
49.93
1 month 43.61
Extreme 43.61
50.16
Current year 18.43
Extreme 18.43
50.16
1 year 13.36
Extreme 13.36
50.16
3 years 13.36
Extreme 13.36
50.16
5 years 13.36
Extreme 13.36
50.16
10 years 13.36
Extreme 13.36
50.16
Manager TitleAgeSince
Chief Executive Officer 53 2024-11-18
Director of Finance/CFO 52 2026-09-01
Chief Tech/Sci/R&D Officer - 2026-06-29
Director TitleAgeSince
Director/Board Member 76 2019-06-30
Director/Board Member 53 2023-07-31
Director/Board Member 53 2024-11-18
Date Insider Type Main position Quantity % Market Cap. Importance
7/30/26
Deep Track Capital LP
BuyCompany 286,205 0.8872%
6/3/26 Free

Director

12,500 0.0557%
6/3/26 Free

Chairman

10,000 0.0446%
Change 5-day change 1-year change 3-year change Capi.($)
+3.83%+4.40% - - 1.59B
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+35.89%+81.43% 64.94B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
-1.42%-0.74%+31.24%+15.84% 25.74B
-1.11%+0.90%+22.24%-18.50% 20.09B
+1.15%-5.02%+219.82%+379.02% 17.16B
+0.20%-1.37%-6.41%+549.54% 14.92B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.01%+1.23%+42.28%+181.77% 28.07B
Weighted average by Cap. -0.79%+0.48%+37.32%+140.48%

Financials

2026 *2027 *
Net sales - -
Net income -176M -152M -143M -130M -243M -16.66B -244M -1.69B -653M -8.53B -662M -647M -27.18B -191M -164M -154M -141M -263M -18.03B -264M -1.83B -707M -9.23B -716M -700M -29.4B
Net Debt -355M -305M -287M -262M -490M -33.57B -492M -3.4B -1.32B -17.19B -1.33B -1.3B -54.77B -506M -436M -410M -374M -699M -47.89B -702M -4.86B -1.88B -24.53B -1.9B -1.86B -78.12B
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
49
Date Price Change Volume
26-09-04 US$49.34 +3.83% 205,964
26-09-03 US$47.52 -3.96% 282,475
26-09-02 US$49.48 +5.05% 518,387
26-09-01 US$47.10 -0.34% 201,986
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
49.34USD
Average target price
53.38USD
Spread / Average Target
+8.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LBRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!